Eesti - eesti - Ravimiamet

venus pharma gmbh - meropeneem - süste-/infusioonilahuse pulber - 1000mg 10tk

Eesti - eesti - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 2g 10tk; 2g 1tk; 2g 5tk

Eesti - eesti - Ravimiamet

venus pharma gmbh - tseftriaksoon - süste-/infusioonilahuse pulber - 1g 5tk; 1g 1tk; 1g 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - takroliimus - kõvakapsel - 1mg 20tk; 1mg 60tk; 1mg 100tk

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - takroliimus - kõvakapsel - 0,5mg 100tk

Eesti - eesti - Ravimiamet

pharmaswiss ceska republika s.r.o. - takroliimus - kõvakapsel - 5mg 60tk; 5mg 30tk; 5mg 100tk; 5mg 50tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - dotsetakseel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastilised ained - rindade cancerdocetaxel teva pharma monotherapy on näidustatud ravi patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise rinnavähi pärast rikke tsütotoksiline ravi. eelmine keemiaravi peaks sisaldama antratsükliini või alküülivat ainet. non-small-cell lung cancerdocetaxel teva pharma on näidustatud ravi patsientidel, kellel on lokaalselt kaugelearenenud või metastaatilise mitte-small-cell lung cancer pärast rikke enne keemiaravi. docetaxel teva pharma koos cisplatin on näidustatud patsientide raviks unresectable, lokaalselt kaugelearenenud või metastaatilise mitte-small-cell lung cancer, patsientidel, kes ei ole varem saanud keemiaravi selle seisukord. eesnäärme cancerdocetaxel teva pharma kombinatsioonis prednisooni või prednisolooni on näidustatud patsientide raviks hormoon tulekindlad metastaatilise eesnäärmevähiga.

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - ravimid hingamisteede obstruktiivsete haiguste, - budesonide / formoterol teva pharma b. on näidustatud ainult 18-aastastel ja vanematel täiskasvanutel. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merz pharmaceuticals gmbh   - memantiinvesinikkloriid - alzheimeri tõbi - muud dementsusevastased ravimid - mõõduka kuni raske alzheimeri tõvega patsientide ravi.